LCTX Lineage Cell Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: LCTX

Price (delayed)

$1.06

Market cap

$199.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.12

Enterprise value

$167.36M

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house ...

Highlights
The debt has contracted by 24% YoY and by 4.2% from the previous quarter
LCTX's EPS is up by 20% year-on-year and by 8% since the previous quarter
The gross profit has contracted by 41% YoY
The revenue has contracted by 39% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://lineagecell.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LCTX
Market
Shares outstanding
188.53M
Market cap
$199.85M
Enterprise value
$167.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
20.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.71
Earnings
Revenue
$8.95M
EBIT
-$23.29M
EBITDA
-$22.6M
Free cash flow
-$29.24M
Per share
EPS
-$0.12
Free cash flow per share
-$0.17
Book value per share
$0.36
Revenue per share
$0.05
TBVPS
$0.25
Balance sheet
Total assets
$101.02M
Total liabilities
$39M
Debt
$2.95M
Equity
$63.42M
Working capital
$20.48M
Liquidity
Debt to equity
0.05
Current ratio
2.14
Quick ratio
2.02
Net debt/EBITDA
1.44
Margins
EBITDA margin
-252.6%
Gross margin
92.5%
Net margin
-240.2%
Operating margin
-276.5%
Efficiency
Return on assets
-19.9%
Return on equity
-31.3%
Return on invested capital
-285.4%
Return on capital employed
-28%
Return on sales
-260.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
0.95%
1 week
-7.02%
1 month
-22.06%
1 year
-27.4%
YTD
-2.75%
QTD
-28.38%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$8.95M
Gross profit
$8.27M
Operating income
-$24.73M
Net income
-$21.49M
Gross margin
92.5%
Net margin
-240.2%
LCTX's operating margin has dropped by 80% year-on-year but it is up by 3% since the previous quarter
The gross profit has contracted by 41% YoY
The revenue has contracted by 39% YoY
The net margin has contracted by 34% YoY but it has grown by 9% from the previous quarter

Growth

What is Lineage Cell Therapeutics's growth rate over time

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
2.92
P/S
20.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.71
LCTX's EPS is up by 20% year-on-year and by 8% since the previous quarter
LCTX's equity is down by 14% YoY and by 7% QoQ
LCTX's P/B is 12% above its 5-year quarterly average of 2.6 but 9% below its last 4 quarters average of 3.2
LCTX's price to sales (P/S) is 69% less than its 5-year quarterly average of 66.7 and 8% less than its last 4 quarters average of 22.2
The revenue has contracted by 39% YoY

Efficiency

How efficient is Lineage Cell Therapeutics business performance
Lineage Cell Therapeutics's ROIC has plunged by 127% from the previous quarter and by 12% YoY
LCTX's ROS is down by 49% year-on-year but it is up by 8% since the previous quarter
LCTX's return on equity is up by 4.3% year-on-year and by 3.4% since the previous quarter

Dividends

What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LCTX.

Financial health

How did Lineage Cell Therapeutics financials performed over time
LCTX's total assets is 159% greater than its total liabilities
Lineage Cell Therapeutics's quick ratio has decreased by 34% YoY and by 23% QoQ
The current ratio has declined by 32% year-on-year and by 22% since the previous quarter
The debt is 95% less than the equity
The debt has contracted by 24% YoY and by 4.2% from the previous quarter
LCTX's equity is down by 14% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.